SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of 67 Cu-SAR-bisPSMA in patients with metastatic castrate resistant prostate cancer.

64/67Cu SAR-bisPSMA theranostic - Clarity Pharma

https://meetings.asco.org/abstracts-presentations/238472/

Geoffrey Johnson; Eva Lengyelova; Luke Nordquist; Vikas Prasad; Monique Anderson; Othon Gervasio; Michelle Parker; Robert M. Miller; A. Oliver Sartor; Scott T. Tagawa

Apr 25, 2024